Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Drug-coated Balloon Angioplasty in Sri Lanka
Author(s): Yanushka Herath , Judy Ranaweera , Thisal Semina , et al Added: 2 weeks ago

Intervention

Prevention & Chronic Conditions
CRT 25: 2Y Outcomes of Prevail Paclitaxel-Coated Balloon VS Contemporary DCB
Author(s): Sacharias Von Koch Added: 9 months ago
CRT 25 - Two-year outcomes of the Prevail paclitaxel-coated balloon show no difference in clinical outcomes compared to other drug-coated balloons (DCBs), suggesting the Prevail DCB is as effective and safe as other contemporary DCB's in a real-world setting. The Prevail DCB was also associated with lower rates of myocardial infarction in the sub-group analysis of patients who also underwent… View more

Intervention
ESC 25: SWEDEPAD 1 and 2
Author(s): Marten Falkenberg , Joakim Nordanstig Added: 3 months ago
ESC Congress 2025 - Paclitaxel-coated devices in critical limb threatening ischemia were not effective in preventing amputation, nor improving quality-of-life in intermittent claudication.Dr Mårten Falkenberg (Sahlgrenska University Hospital, Gothenburg, SE) and Prof Joakim Nordanstig (Sahlgrenska University Hospital, Gothenburg, SE) join us to discuss findings from the SWEDEPAD 1 and 2 parallel… View more

Intervention

Vascular Disease and Surgery
Paclitaxel-Coated Devices Do Not Reduce Amputation Risk in Chronic Limb-Threatening Ischaemia
Added: 2 months ago Source:  Radcliffe Vascular
The use of paclitaxel-coated devices for infrainguinal endovascular revascularisation does not reduce the rate of major amputation or all-cause mortality in patients with chronic limb-threatening ischaemia (CLTI), according to findings from a large registry-based trial in Sweden.¹ Peripheral artery disease (PAD) is a significant global health issue, and for patients with its most severe form,… View more

Intervention

Vascular Disease and Surgery
SWEDEPAD 1: Paclitaxel-Coated Devices Show No Benefit in Reducing Amputation for CLTI
Added: 3 months ago Source:  Transcatheter Academy
The use of paclitaxel-coated devices did not reduce the rate of major amputations or death in patients with chronic limb-threatening ischaemia (CLTI) undergoing infrainguinal endovascular revascularisation, according to the results of a large registry-based trial.¹ While drug-coated devices are commonly used in peripheral interventions, their effect on amputation risk has been uncertain.²The… View more

Cardiovascular Renal Metabolic

Intervention
TCT 24: Sirolimus- vs. Paclitaxel-Coated Balloon Angioplasty
Author(s): Ulf Teichgräber Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of the trial shows that percutaneous transluminal angioplasty (PTA) with the sirolimus drug coated balloon (DCB) in patients with femoropopliteal artery disease was/was not noninferior to PTA with the paclitaxel DCB.Prof Ulf Teichgräber joins us onsite at TCT Conference to discuss the findings from the sirolimus- vs. paclitaxel-coated balloon… View more

Intervention

Vascular Disease and Surgery
ISET 25: Drug Delivery Devices: Paclitaxel Drug-Coated Balloons and Drug-Eluting Stents
Author(s): Marianne Brodmann Added: 10 months ago
ISET 2025 - How have drug delivery devices changed over the years, and what are the novel technologies and therapeutic agents?Dr Marianne Brodmann (Medical University of Graz, AT) joins us onsite at ISET 2025 to discuss the current landscape of drug delivery devices, from paclitaxel drug-coated balloons to drug-eluting stents. Dr Brodmann discusses evolving technologies, including bioresorbable… View more

Intervention

Vascular Disease and Surgery
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 2 years ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
Andrew JS Coats
Job title: Professor of Cardiology and Scientific Director
Professor Andrew Coats was born in Melbourne, Australia. He studied at St Catherine’s College, Oxford, where he earned a B.A. in Physiological Sciences with First-Class Honours, and then completed his medical degree (M.B. B.Chir.) at Clare College, Cambridge. He later obtained higher doctorates (D.M. and D.Sc.) in recognition of his substantial contributions to cardiovascular medicine, and he… View more
New Data Supports Prevail DCB's Safety and Efficacy
Author(s): Matthias Götberg Added: 1 month ago
Prof Matthias Götberg (Interventional Cardiologist at Skane University Hospital, Lund, SE) provides an overview of the recent two-year data presented from the SCAAR registry and an overview of the bifurcation subset analysis that was presented at EuroPCR in May 2025.Prof Götberg is a contributor to The Swedish Coronary Angiography and Angioplasty Registry (SCAAR), he discusses the key findings… View more

Intervention